Allogene Therapeutics logo

Allogene Therapeutics Funding & Investors

Allogene Therapeutics, Inc. operates as a biotechnology company. The Company develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. Allogene Therapeutics serves patients in the State of California.

allogene.com

Total Amount Raised: $531,770,400

Allogene Therapeutics Funding Rounds

  • Convertible Note

    $120,000,000

    Convertible Note Investors

    Perceptive Advisors
    Deerfield Capital Management
    Fidelity Investments
    Jennison Associates
    Franklin Resources
    T. Rowe Price
    Surveyor Capital
    venBio Select Advisor
    Cowen Investment Management
  • Series A

    $411,770,409

    Series A Investors

    TPG
    Vida Ventures
    Pfizer
    Two River
    Bellco Capital
    Gilead Sciences
Funding info provided by Diffbot.